Depomed, Inc. (DEPO) Insider Arthur J. Higgins Purchases 75,000 Shares of Stock
Depomed, Inc. (NASDAQ:DEPO) insider Arthur J. Higgins acquired 75,000 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were bought at an average cost of $8.16 per share, for a total transaction of $612,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
Depomed, Inc. (DEPO) traded up $0.22 during trading on Friday, reaching $8.38. The company’s stock had a trading volume of 2,220,465 shares, compared to its average volume of 1,740,255. The company has a debt-to-equity ratio of 2.90, a current ratio of 0.83 and a quick ratio of 0.79. Depomed, Inc. has a 52 week low of $4.31 and a 52 week high of $21.38.
Depomed (NASDAQ:DEPO) last released its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Depomed had a negative return on equity of 51.07% and a negative net margin of 27.73%. The company had revenue of $95.40 million during the quarter, compared to analysts’ expectations of $99.11 million. During the same period last year, the business posted $0.28 earnings per share. The firm’s revenue was down 13.7% compared to the same quarter last year. equities analysts predict that Depomed, Inc. will post -1.34 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the business. Sivik Global Healthcare LLC purchased a new position in shares of Depomed in the second quarter worth about $1,933,000. Systematic Financial Management LP purchased a new position in shares of Depomed in the second quarter worth about $1,801,000. State of Wisconsin Investment Board raised its stake in shares of Depomed by 155.0% in the second quarter. State of Wisconsin Investment Board now owns 515,200 shares of the specialty pharmaceutical company’s stock worth $5,533,000 after purchasing an additional 313,200 shares during the last quarter. Ballentine Partners LLC purchased a new position in shares of Depomed in the second quarter worth about $442,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Depomed in the second quarter worth about $2,834,000. Institutional investors own 90.99% of the company’s stock.
DEPO has been the topic of a number of recent research reports. Piper Jaffray Companies reaffirmed a “hold” rating and set a $9.00 price objective on shares of Depomed in a research report on Sunday, September 10th. ValuEngine raised Depomed from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. Mizuho reiterated a “neutral” rating and issued a $6.00 price target (down from $11.00) on shares of Depomed in a research note on Friday, October 13th. Royal Bank of Canada set a $10.00 price target on Depomed and gave the company a “hold” rating in a research note on Friday, October 20th. Finally, Morgan Stanley upgraded Depomed from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $11.64.
COPYRIGHT VIOLATION WARNING: “Depomed, Inc. (DEPO) Insider Arthur J. Higgins Purchases 75,000 Shares of Stock” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/12/16/depomed-inc-depo-insider-arthur-j-higgins-purchases-75000-shares-of-stock.html.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.